incorporated in 2018, cytomed therapeutics is a spin-off from singapore’s agency for science, technology and research ( a*star) and focuses on translating its patented technologies into gamma delta (γδ) t cell- and natural killer (nk) cell-based “off-the-shelf” immunotherapeutics for a wide range of cancers. we also engage in generating induced pluripotent stem cells (ipscs) and translating them into “off-the-shelf” cellular therapeutics using our proprietary technologies for our customers.
Company profile
Ticker
GDTC
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CytoMed Therapeutics Pte. Ltd.
SEC CIK
GDTC stock data
Latest filings (excl ownership)
6-K
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
18 Mar 24
6-K
Current report (foreign)
4 Mar 24
6-K
Malaysian Patent Granted for CytoMed Therapeutics’ Licensed Allogeneic CAR-Gamma Delta T Cell Technology
29 Jan 24
6-K
Current report (foreign)
17 Nov 23
6-K
Chinese Patent Granted for CytoMed Therapeutics’ Licensed iPSC-based Technology
25 Sep 23
6-K
Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics’ Licensed Allogeneic CAR-Gamma Delta T Cell Technology
1 Aug 23
6-K
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US
6 Jul 23
20-F
2022 FY
Annual report (foreign)
1 May 23
6-K
Cytomed Therapeutics Limited Announces Pricing of Initial Public Offering
18 Apr 23
424B4
Prospectus supplement with pricing info
17 Apr 23
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
News
CytoMed Therapeutics Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
4 Mar 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
14 Feb 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
9 Feb 24
Why Container Store Group Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
7 Feb 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
7 Feb 24
Press releases
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration
20 Mar 24
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
18 Mar 24
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
4 Mar 24